Scientia U. Lin, N, K. Murthy, R, Abramson, V, Anders, C, Bachelot, T, L. Bedard, P, Borges, V, Cameron, D A, A. Carey, L, Chien, J, Curigliano, G, P. Di Giovanna, M, Gelmon, K, Hortobagyi, G, A. Hurvitz, S, Krop, I, Loi, S, Loibl, S, Mueller, V, Oliveira, M, Paplomata, E, Pegram, M, Slamon, D, Zelnak, A, Ramos, J, Feng, W & Winer, E 2022, ' Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain MetastasesUpdated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial ', JAMA Oncology . https://doi.org/10.1001/jamaoncol.2022.5610
Journal of Clinical Oncology Scientia Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 23 Lin, N U, Borges, V, Anders, C, Murthy, R K, Paplomata, E, Hamilton, E, Hurvitz, S, Loi, S, Okines, A, Abramson, V, Bedard, P L, Oliveira, M, Mueller, V, Zelnak, A, Digiovanna, M P, Bachelot, T, Chien, A J, O’regan, R, Wardley, A, Conlin, A, Cameron, D, Carey, L, Curigliano, G, Gelmon, K, Loibl, S, Mayor, J, Mcgoldrick, S, An, X & Winer, E P 2020, ' Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial ', Journal of Clinical Oncology, pp. JCO.20.00775 . https://doi.org/10.1200/JCO.20.00775, https://doi.org/10.1200/JCO.20.00775 BASE-Bielefeld Academic Search Engine
Mueller, V, Wardley, A, Paplomata, E, Hamilton, E, Zelnak, A, Fehrenbacher, L, Jakobsen, E, Curtit, E, Boyle, F, Harder Brix, E, Brenner, A, Crouzet, L, Ferrario, C, Muñoz-Mateu, M, Arkenau, H T, Iqbal, N, Aithal, S, Block, M, Cold, S, Cancel, M, Hahn, O, Poosarla, T, Stringer-Reasor, E, Colleoni, M, Cameron, D, Curigliano, G, Siadak, M, DeBusk, K, Ramos, J, Feng, W & Gelmon, K 2021, ' Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial) ', European Journal of Cancer, vol. 153, pp. 223-233 . https://doi.org/10.1016/j.ejca.2021.05.025